Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma
BenzingaApr 26 13:56 ET
PEGY, CGEM and IFBD Among Mid-day Movers
Seeking AlphaApr 26 13:09 ET
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
BenzingaApr 26 08:55 ET
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
BenzingaApr 25 19:50 ET
ZyVersa Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 26th, 2024
April 25th - $ZyVersa Therapeutics(ZVSA.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 26th, 2024.$ZyVersa Ther
moomoo NewsApr 24 19:40 ET
ZyVersa Therapeutics Approves Reverse Stock Split
TipRanksApr 17 16:42 ET
Buy Rating Affirmed: ZyVersa Therapeutics' Promising Pipeline and Strategic Advancements
TipRanksMar 26 06:17 ET
Express News | HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target
Moomoo 24/7Mar 26 06:16 ET
Zyversa Therapeutics' 1-for-35 Reverse Split: Navigating the Risks to Shareholder Value and Liquidity
TipRanksMar 26 02:00 ET
ZyVersa Therapeutics GAAP EPS of -$0.29
Seeking AlphaMar 25 16:07 ET
ZyVersa Therapeutics FY23 EPS $(108.97)
ZyVersa Therapeutics FY23 EPS $(108.97)
BenzingaMar 25 08:26 ET
Press Release: ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Key Highlights: -- Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical tria
Dow JonesMar 25 08:17 ET
Express News | ZyVersa Therapeutics Shares Are Trading Higher After the Company Announced IRB Approval of the Phase 2a Clinical Trial Protocol to Evaluate the Efficacy and Safety of Cholesterol Efflux Mediator VAR 200 in Patients With Diabetic Kidney Disease
Moomoo 24/7Mar 18 10:48 ET
ZyVersa Gets IRB Nod for Kidney Drug Phase 2a Trial
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), a biopharmaceutical company, has received Institutional Review Board (IRB) approval to proceed with a Phase 2a clinical trial for its Cholesterol Efflux Mediator VAR 200, a drug under development for the treatment of diabetic kidney disease.
Investing.com Mar 18 08:08 ET
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients With Diabetic Kidney Disease
Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic
GlobeNewswireMar 18 07:57 ET
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled "Inflammation Illuminated,"at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024
According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is developing Inflammasome ASC
GlobeNewswireMar 14 07:57 ET
ZyVersa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ZyVersa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 12 08:33 ET
Express News | HC Wainwright & Co. Maintains Buy on ZyVersa Therapeutics, Lowers Price Target to $12
Moomoo 24/7Mar 12 08:24 ET
ZyVersa Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/12/2024 1295.19% HC Wainwright & Co. $24 → $12 Maintains Buy 02/29/2024 2690.37% HC Wainwright & Co. →
BenzingaMar 12 08:22 ET
Analysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)
TipRanksMar 12 06:30 ET
No Data
No Data